Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1115-3842 | Other Identifier | UTN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary Objective:
- To evaluate safety (4 weeks)
Secondary Objectives:
The study consists of four phases: up to 9-day screening phase, main 4-week treatment phase, up-to 8-week extension phase, and up-to 5-day post-treatment phase.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Age 6 months - 2 years | Experimental | Patients between 6 months and 2 years old |
|
| Age 2 - 11 years | Experimental | Patients between 2 and 11 years (and under 10.5 kg) |
|
| Age 2 - 11 years (and over 10.5 kg) | Experimental | Patients between 2 and 11 years (and over 10.5 kg) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| fexofenadine/Allegra (M016455) | Drug | Pharmaceutical form:dry syrup formulation to be suspended in water Route of administration: oral |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with adverse events | 4 weeks | |
| The number of clinically significant abnormalities for laboratory findings | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with adverse events | 12 weeks | |
| The number of clinically significant abnormalities for laboratory findings | 12 weeks | |
| Changes from baseline in nasal symptom scores on patient diary |
Not provided
Inclusion criteria:
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Sciences & Operations | Sanofi | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sanofi-Aventis Investigational Site Number 392015 | Fukuoka | Japan | ||||
| Sanofi-Aventis Investigational Site Number 392012 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 4 weeks |
| Changes from baseline in nasal symptom severity scores assessed by investigator or subinvestigator | week 2 and 4 |
| Pharmacokinetic parameters of fexofenadine at steady state; AUC | week 4 and 12 |
| Kanazawa |
| Japan |
| Sanofi-Aventis Investigational Site Number 392001 | Kawaguchi-Shi | Japan |
| Sanofi-Aventis Investigational Site Number 392003 | Kawasaki-Shi | Japan |
| Sanofi-Aventis Investigational Site Number 392004 | Kawasaki-Shi | Japan |
| Sanofi-Aventis Investigational Site Number 392002 | Kita-ku | Japan |
| Sanofi-Aventis Investigational Site Number 392011 | Kofu | Japan |
| Sanofi-Aventis Investigational Site Number 392014 | Obu-Shi | Japan |
| Sanofi-Aventis Investigational Site Number 392013 | Seki-Shi | Japan |
| Sanofi-Aventis Investigational Site Number 392005 | Yokohama | Japan |
| Sanofi-Aventis Investigational Site Number 392006 | Yokohama | Japan |
| Sanofi-Aventis Investigational Site Number 392007 | Yokohama | Japan |
| Sanofi-Aventis Investigational Site Number 392008 | Yokohama | Japan |
| Sanofi-Aventis Investigational Site Number 392009 | Yokohama | Japan |
| Sanofi-Aventis Investigational Site Number 392010 | Yokohama | Japan |
| ID | Term |
|---|---|
| C093230 | fexofenadine |
Not provided
Not provided
Not provided